Kolon Tissue Gene
Price chart
- MA5
- MA20
- MA60
Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.
Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.
Overview
Summary
Kolon Tissue Gene is a company established in 1999 under Delaware law. It is listed on the KOSDAQ market and is an affiliate of the Kolon Group.
The company develops cell and gene therapies, focusing on the product INVOSSA for osteoarthritis. It also operates a complex distribution business involving health and beauty products and liquor and beverage retail.
Business overview as filed
당사는 세포 유전자 기술인 TG-C Platform을 이용하여 신약개발을 하는 기업으로써 2004년 9월 "TGF-β1을 이용한 유전자치료"로 미국 특허 등록을 획득하였습니다.보고서 제출일 현재 당사는 무릎 골관절염(Knee OA) 적응증에 대한 FDA 임상 3상 시험을 진행중에 있으며, 고관절 골관절염(Hip OA) 적응증은 FDA로부터 임상 2상 승인을 받았습니다.
고관절 골관절염(Hip OA)의 경우, 고관절은 관절의 구조와 질병의 원인 및 진행과정이 무릎 골관절염과 유사합니다. 따라서 당사는 개발이 가장 앞서 있는 무릎 골관절염(Knee OA)에 집중할 계획입니다.
퇴행성 척추 디스크질환(Degenerative Disc Disease, DDD)적응증은 질병의 진행과정이나 기전이 무릎(Knee)이나 고관절(Hip)과는 차이가 있어서 전임상(Preclinical) 부터 진행이 되었습니다. 전임상의 동물실험 결과 손상된 디스크로 인한 통증 반응이 TG-C 주입 후 유의하게 감소되었음을 확인하였으며 당사는 해당 데이터를 바탕으로 FDA에 IND (Investigational New Drug)를 제출하였고 2023년 12월에 이에 대한 승인을 받았습니다.이는 TG-C가 FDA로부터 미국시민을 대상으로 추가 임상을 진행해도 안전(Safety)하다는 검증을 받은 것이라 판단합니다.
[TG-C 개발 진행 현황]
개발현황.jpg 개발현황 당사는 무릎 골관절염(Knee OA) 적응증에 대해 2018년 7월 FDA 임상 3상 시료 사용 허가를 받고 동년 11월 투약을 개시하였으나, TG-C 2액 세포의 기원착오의 가능성으로 인해 2019년 2월 자발적으로 투약 절차를 중단하였고 동년 5월 FDA로부터 Clinical Hold 지정이 되었습니다. 이에 대해 당사는 발생 경위와 세포특성에 대한 추가실험자료 등 FDA의 방대한 요구 자료를 제출함으로써 2020년 4월 FDA로부터 투약 절차를 재개해도 된다는 Remove Clinical Hold Letter를 수령하였습니다.
FDA의 Remove Clinical Hold Letter 수령 이후 임상시험계획서와 환자사전동의서 수정, 임상 시료의 생산 등 임상(Clinical)과 생산(Manufacturing)부분의 준비 절차를 거쳐 당사는 2021년 12월에 무릎골관절염(Knee OA) 임상 3상의 투약을 재개하였습니다. 당사의 임상 3상은 2개의 Pivotal study로 구성이 되어있으며, 2024년 7월 2개의 Pivotal study에 대해 총 1,066명 환자 등록을 완료하였습니다. 보고서제출일 현재 당사는 투약된 환자를 대상으로 TG-C 투여 후 무릎골관절염의 진행 여부 등을 확인하기 위해 각 환자별로 추적관찰을 진행중에 있습니다. 이는 마지막 환자 투여일로부터 2년간 진행될 계획으로, 추적관찰기간이 종료되면 데이터 분석기간을 거쳐 FDA에 품목허가(BLA)를 신청할 계획입니다. 이와 별개로 당사는 신속한 FDA 품목허가(BLA)를 위해 생산(Chemistry, Manufacturing and Control, CMC)분야에서 FDA가 요구하는 사항을 충족하기 위한 준비도 병행하여 진행중에 있습니다. 또한, 당사의 복합유통사업부문은 건강기능식품, 화장품, 생활용품 등을 판매하는 Health & Beauty 사업(W-store)과 와인 등을 전문으로 소매하는 Liquor & Beverage(L&B) 사업을 운영하고 있습니다.
Company overview
가-1. 연결대상 종속회사 개황 연결대상 종속회사 현황 (요약)
가-2. 연결대상회사의 변동내용
나. 중소기업 등 해당 여부
당사는 외국법인으로서 한국법상 중소기업에 해당하지 않습니다.
다. 회사의 법적, 상업적 명칭당사의 명칭은 'Kolon TissueGene, Inc.'라고 표기합니다. 또한 국문으로는 '코오롱티슈진 주식회사' 로 표기합니다. 당사는 1999년 6월 9일에 설립되었으며, 2018년 3월 16일 '티슈진 주식회사(TissueGene, Inc.)'에서 '코오롱티슈진 주식회사(Kolon TissueGene, Inc.)'로 상호 변경하였습니다.
라. 회사의 주소, 전화번호 및 홈페이지(1) 주소: 9713 Key West Ave. Suite 300, Rockville, MD 20850, USA(2) 전화번호: +1-301-921-6000(3) 홈페이지: http://www.tissuegene.com
마. 대리인에 관한 사항당사는 제출일 현재 한국에 지점을 설치하였으며, 공시 업무는 한국지점의 공시책임자 및 담당자를 통해 이행하고 있습니다.
바. 주요사업의 내용당사는 인대손상치료, 연골재생촉진제의 연구, 개발, 생산, 판매 및 생명공학 분야 연구, 개발, 생산, 투자를 목적으로 1999년 6월 9일에 설립되었습니다. 당사의 주력 개발품목인 INVOSSA(이하 'TG-C')는 골관절염 세계 최초 세포 유전자 치료제로 미국 임상을 진행 중에 있습니다. 또한 당사는 코오롱웰케어(주)의 영업을 2017년 08월 01일에 양수함에 따라 공시서류 작성 기준일 현재 복합유통사업을 함께 운영하고 있습니다.
사. 회사의 설립근거법 당사는 델라웨어 주법에 따라 설립된 회사로 델라웨어 회사는 개인, 조합, 사단 또는 회사(거주지, 주소지 또는 설립 주를 불문)가 단독으로 또는 다른 자와 공동으로, 규정된 절차에 따라 기본정관을 작성, 승인하고 이를 델라웨어 주 정부 회사부(Division of Corporations)에 제출함으로서 설립할 수 있습니다.
아. 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항
자. 계열회사에 관한 사항공시서류 작성 기준일 현재 당사의 최대주주는 (주)코오롱으로 독점규제및공정거래에관한법률상 코오롱그룹에 속한 계열회사입니다. 코오롱그룹에는 당사를 포함한 국내 40개의 계열회사와 해외 44개의 계열회사가 소속되어 있으며 그 상세 현황은 다음과 같습니다.
Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.18), tables and figures omitted.
- The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
- The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.
VaR
The headline's measure for each of the three windows on one scale, the dot being the estimate and the bar its interval. The windows are nested and share their observations, so the three readings are not three independent measurements. The selected window is highlighted.
The issue's daily returns over the chosen window counted into equal-width bins. The vertical lines mark the VaR and cVaR above on the loss side. The published VaR sample applies exclusion rules for halts and first sessions that this raw daily series does not, so the bars and the marks can differ slightly at the edges.
Deepest drawdown 91.6% (2026-07-30). How far below its previous peak the issue stood each day over the chosen window, a description of the path already travelled.
Characteristic line
- Intercept
- -0.229%[-1.255%, +0.796%]
- R squared
- 0.22
- Observations
- 252
- Trading-time corrected beta
- 1.12[0.77, 1.47]
A 252-day window rolled one day at a time over the longest daily span of the characteristic line. It shows when the beta against the KOSDAQ150 and the annualized volatility of the issue's excess return rose and fell, and unlike the headline figures above it carries no interval.
Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.
- Beta summarizes by regression how far the issue's return moved together with the KOSPI200 or KOSDAQ150 index return, and the index is only a stand-in for the whole market.
- The intercept is the average excess return the index does not explain, and when the interval shown beside it contains zero it cannot be told apart from zero.
- Beta and the intercept are computed from the sample of the chosen window and frequency and are not values for the period ahead.
- At the daily frequency a beta corrected for differences in trading times is shown alongside, and the gap between the two shows how much later than the index the issue's trades are reflected.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,455,989 USD | 2,822,887 USD | 3,440,200 USD | 2,619,408 USD | 3,013,298 USD | 3,497,973 USD | 7,319,202 USD | 2,839,000 USD | 3,719,583 USD | 3,627,220 USD | 3,314,324 USD |
| Revenue growth% | — | -75.36 | 21.87 | -23.86 | 15.04 | 16.08 | 109.24 | -61.21 | 31.02 | -2.48 | — |
| Operating income | -3,383,998 USD | -36,029,293 USD | -29,937,807 USD | -38,192,414 USD | -35,215,717 USD | -40,984,035 USD | -12,618,990 USD | -15,707,145 USD | -16,127,329 USD | -15,695,998 USD | -16,561,515 USD |
| Net income | -2,259,777 USD | -40,176,191 USD | -29,324,152 USD | -42,268,273 USD | -35,412,429 USD | -41,391,802 USD | -8,619,693 USD | -13,194,601 USD | -24,779,552 USD | -135,413,281 USD | -125,917,023 USD |
| Attributable to owners | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Attributable to minorities | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Operating margin% | -29.54 | -1,276.33 | -870.23 | -1,458.06 | -1,168.68 | -1,171.65 | -172.41 | -553.26 | -433.58 | -432.73 | -499.70 |
| Net margin% | -19.73 | -1,423.23 | -852.40 | -1,613.66 | -1,175.21 | -1,183.31 | -117.77 | -464.76 | -666.19 | -3,733.25 | -3,799.18 |
| ROE | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| ROA% | -9.29 | -22.36 | -19.92 | -39.30 | -52.90 | -79.92 | -9.94 | -12.61 | -16.39 | -45.83 | -37.82 |
| Debt ratio% | 234.73 | 20.25 | 19.91 | 33.11 | 51.41 | 58.87 | 20.11 | 17.35 | 52.35 | 561.65 | 151.42 |
| Current ratio% | 784.34 | 1,464.76 | 1,204.81 | 805.68 | 414.64 | 269.15 | 543.53 | 223.94 | 10.43 | 24.26 | 33.25 |
| Quick ratio% | 784.34 | 1,458.31 | 1,198.82 | 801.87 | 412.40 | 268.10 | 543.39 | 223.49 | 10.30 | 24.24 | 33.23 |
| Reserve ratio% | 9,925.91 | 6,260,976.23 | 5,125,549.90 | 3,363,458.48 | 1,849,510.84 | 1,326,346.14 | 2,835,092.40 | 3,397,353.84 | 3,585,606.25 | 1,573,879.68 | 4,605,180.22 |
| Free cash flow | -3,220,503 USD | -34,618,867 USD | -31,495,077 USD | -39,352,417 USD | -33,008,754 USD | -35,448,492 USD | -20,778,013 USD | -18,668,191 USD | -15,088,919 USD | -17,725,984 USD | — |
| FCF margin% | -28.11 | -1,226.36 | -915.50 | -1,502.34 | -1,095.44 | -1,013.40 | -283.88 | -657.56 | -405.66 | -488.69 | — |
| Capex to revenue% | 1.80 | 10.42 | 12.57 | 65.98 | 23.25 | 13.69 | 0.72 | 7.03 | 2.55 | 23.19 | — |
| Receivable daysdays | — | 59.6 | 81.7 | 239.0 | 206.8 | 46.4 | 16.0 | 86.9 | 57.8 | 18.7 | — |
| Inventory daysdays | — | 96.3 | 122.2 | 87.9 | 52.5 | 26.8 | 21.0 | 4.6 | 6.3 | 6.1 | — |
| Payable daysdays | — | 1,141.0 | 1,089.1 | 976.0 | 968.5 | 1,192.6 | 2,638.7 | 1,135.7 | 1,497.7 | 1,787.0 | — |
| Cash conversion cycledays | — | -985.1 | -885.2 | -649.0 | -709.2 | -1,119.4 | -2,601.8 | -1,044.2 | -1,433.7 | -1,762.2 | — |
| EPS | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| PER | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| BPS | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| PBR | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Dividend per share | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
Separate basis
Periods filed in a currency other than the won are shown as filed with the code beside the figure, and the per-share rows and multiples are not computed for those periods.
Financial statements
Balance sheet
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 24,314,618 USD | 179,695,446 USD | 147,233,191 USD | 107,563,251 USD* | 66,947,239 USD | 51,792,050 USD | 86,711,825 USD | 104,630,356 USD | 151,216,411 USD | 295,484,173 USD | |
| 19,978,854 USD | 176,731,213 USD | 140,003,612 USD | 97,421,237 USD* | 57,917,520 USD | 36,650,308 USD | 49,767,208 USD | 24,841,461 USD | 5,044,454 USD | 60,137,913 USD | |
| Cash and cash equivalents | 19,428,528 USD | 26,735,368 USD | 18,244,010 USD | 39,312,835 USD | 17,023,998 USD | 32,739,992 USD | 32,796,306 USD | 21,275,420 USD | 546,173 USD | 47,210,417 USD |
| Short-term financial instruments | 0 USD | 146,000,000 USD | 117,064,218 USD | 51,423,755 USD | 34,750,000 USD | 168,727 USD | 13,177,622 USD | 0 USD | — | 10,000,000 USD |
| Inventories | 0 USD | 778,167 USD | 695,348 USD | 460,674 USD* | 313,966 USD | 143,885 USD | 13,067 USD | 49,852 USD | 63,575 USD | 42,150 USD |
| Trade and other receivables | 0 USD | 922,278 USD | 616,954 USD | 2,814,037 USD* | 600,585 USD | 288,543 USD | 353,888 USD | 997,823 USD | 179,304 USD | 192,037 USD |
| 4,335,764 USD | 2,964,233 USD | 7,229,579 USD | 10,142,014 USD* | 9,029,719 USD | 15,141,742 USD | 36,944,617 USD | 79,788,895 USD | 146,171,957 USD | 235,346,260 USD | |
| Property, plant and equipment | 713,340 USD | 957,095 USD | 937,893 USD | 2,523,100 USD* | 2,377,678 USD | 2,305,313 USD | 1,812,435 USD | 1,459,573 USD | 1,424,711 USD | 1,459,677 USD |
| Intangible assets | 290,335 USD | 1,055,410 USD | 5,303,600 USD | 335,857 USD* | 255,145 USD | 5,054,870 USD | 24,638,779 USD | 67,988,947 USD | 136,233,277 USD | Not applicable |
| 17,050,725 USD | 30,258,478 USD | 24,445,958 USD | 26,753,496 USD* | 22,730,082 USD | 19,191,687 USD | 14,519,975 USD | 15,469,987 USD | 51,962,208 USD | 250,825,311 USD | |
| 2,547,232 USD | 12,065,518 USD | 11,620,406 USD | 12,091,770 USD* | 13,967,980 USD | 13,616,963 USD | 9,156,213 USD | 11,093,030 USD | 48,374,639 USD | 247,878,986 USD | |
| Trade and other payables | 2,257,651 USD | 6,959,768 USD | 6,171,346 USD | 6,664,559 USD* | 7,631,597 USD | 12,724,973 USD | 7,028,190 USD | 8,668,879 USD | 18,279,652 USD | 12,519,612 USD |
| Short-term borrowings | 0 USD | 4,500,000 USD | 5,000,000 USD | 5,000,000 USD | 5,000,000 USD | 0 USD | 0 USD | — | — | — |
| Current lease liabilities | — | — | — | 106,240 USD* | 631,416 USD | 552,440 USD | 631,375 USD | 703,923 USD | 729,517 USD | 845,207 USD |
| 14,503,493 USD | 18,192,960 USD | 12,825,552 USD | 14,661,726 USD* | 8,762,102 USD | 5,574,724 USD | 5,363,762 USD | 4,376,957 USD | 3,587,569 USD | 2,946,325 USD | |
| Long-term borrowings | 14,000,000 USD | 17,500,000 USD | 12,500,000 USD | 7,500,000 USD | 2,500,000 USD | 0 USD | 395,424 USD | — | — | — |
| Non-current lease liabilities | — | — | — | 7,089,119 USD* | 6,109,529 USD | 5,548,575 USD | 4,950,189 USD | 4,318,208 USD | 3,587,569 USD | 2,888,632 USD |
| 7,263,893 USD | 149,436,968 USD | 122,787,233 USD | 80,809,755 USD* | 44,217,157 USD | 32,600,363 USD | 72,191,850 USD | 89,160,369 USD | 99,254,203 USD | 44,658,862 USD | |
| Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | |
| Issued capital | 72,464 USD | 2,385 USD | 2,397 USD | 2,399 USD | 2,399 USD | 2,471 USD | 2,554 USD | 2,630 USD | 2,768 USD | 2,840 USD |
| Capital surplus | 71,218,635 USD | 253,543,212 USD | 256,303,248 USD | 256,524,269 USD* | 256,541,292 USD | 286,449,021 USD | 334,699,139 USD | 364,866,149 USD | 399,611,796 USD | 480,574,288 USD |
| Retained earnings | -64,025,921 USD | -104,218,929 USD | -133,443,817 USD | -175,834,900 USD* | -212,171,527 USD | -253,675,008 USD | -262,290,879 USD | -275,515,743 USD | -300,362,215 USD | -435,876,105 USD |
| Accumulated other comprehensive income | -1,285 USD | 110,300 USD | -74,595 USD | 117,987 USD* | -155,007 USD | -176,121 USD | -218,964 USD | -192,667 USD | 1,854 USD | -42,161 USD |
| Non-controlling interests | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| 당기법인세자산As filed | — | — | 588 USD | 337 USD | 20 USD | 254 USD | 1,821 USD | 713 USD | 429 USD | 4,888 USD |
| 기타금융자산As filed | 154 USD | 34,983 USD | 59,983 USD | 13,484 USD | 0 USD | 0 USD | 0 USD | — | — | — |
| 기타유동자산As filed | 550,326 USD | 2,295,400 USD | 3,382,494 USD | 3,396,115 USD | 5,228,951 USD | 3,308,907 USD | 3,424,504 USD | 2,517,653 USD | 4,254,973 USD | 2,688,421 USD |
| 기타유동금융자산As filed | — | — | — | — | — | 0 USD | — | — | — | — |
| 순확정급여자산As filed | — | — | 21,754 USD | 0 USD | 38,939 USD | 19,648 USD | 40,392 USD | 20,153 USD | 10,385 USD | 0 USD |
| 기타비유동자산As filed | 17,548 USD | 916,745 USD | 906,349 USD | 425,843 USD | 281,332 USD | 2,521,598 USD | 5,829,255 USD | 6,303,527 USD | 5,186,302 USD | 13,674,084 USD |
| 매출채권및기타채권As filed | 0 USD | 0 USD | — | — | — | — | — | — | — | — |
| 무형자산As filed | — | — | — | — | — | — | — | — | — | 217,405,771 USD |
| 사용권자산As filed | — | — | — | 6,810,715 USD | 6,016,125 USD | 5,240,313 USD | 4,623,756 USD | 4,016,695 USD | 3,317,282 USD | 2,806,728 USD |
| 이연법인세자산As filed | 3,314,387 USD | 0 USD | 0 USD | — | — | — | — | — | — | — |
| 부채와자본총계As filed | 24,314,618 USD | 179,695,446 USD | 147,233,191 USD | 107,563,251 USD | 66,947,239 USD | 51,792,050 USD | 86,711,825 USD | 104,630,356 USD | 151,216,411 USD | — |
| 유동파생상품부채As filed | — | — | — | — | — | — | — | — | 20,280,557 USD | 178,539,308 USD |
| 유동성전환사채As filed | — | — | — | — | — | — | — | — | 7,411,034 USD | 51,713,498 USD |
| 자본과부채총계As filed | — | — | — | — | — | — | — | — | — | 295,484,173 USD |
| 기타 유동부채As filed | — | — | — | — | — | — | — | 1,684,787 USD | 1,658,467 USD | 4,228,888 USD |
| 기타유동부채As filed | 289,581 USD | 548,873 USD | 324,515 USD | 254,600 USD | 602,896 USD | 316,253 USD | 1,472,038 USD | — | — | — |
| 충당부채As filed | 0 USD | 56,877 USD | 124,545 USD | 66,371 USD | 102,071 USD | 23,297 USD | 24,610 USD | 35,441 USD | 15,412 USD | 32,473 USD |
| 매입채무 및 기타채무As filed | 503,493 USD | 595,151 USD | 325,398 USD | — | — | — | — | — | — | — |
| 순확정급여부채As filed | 0 USD | 97,809 USD | 0 USD | 72,607 USD | 0 USD | 0 USD | — | — | — | 57,693 USD |
| 장기매입채무및기타채무As filed | — | — | — | — | — | — | — | 58,749 USD | — | — |
| 기타비유동부채As filed | — | — | 154 USD | 0 USD | 152,573 USD | 26,149 USD | 18,149 USD | — | — | — |
| 기타채무As filed | — | — | — | 0 USD | — | — | — | — | — | — |
| 기타 비유동 부채As filed | — | — | — | — | — | — | — | 0 USD | — | — |
| 장기매입채무 및 기타비유동채무As filed | — | — | — | — | 0 USD | — | — | — | — | — |
Income statement
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11,455,989 USD | 2,822,887 USD | 3,440,200 USD | 2,619,408 USD* | 3,013,298 USD | 3,497,973 USD | 7,319,202 USD | 2,839,000 USD | 3,719,583 USD | 3,627,220 USD | |
| Cost of sales | 0 USD | 1,474,242 USD | 2,200,428 USD | 2,400,244 USD* | 2,693,885 USD | 3,114,999 USD | 1,366,166 USD | 2,522,466 USD | 3,283,736 USD | 3,145,406 USD |
| Gross profit | 11,455,989 USD | 1,348,645 USD | 1,239,772 USD | 219,164 USD* | 319,413 USD | 382,974 USD | 5,953,036 USD | 316,534 USD | 435,847 USD | 481,814 USD |
| SG&A expenses | 14,839,987 USD | 37,377,938 USD | 31,177,579 USD | 38,411,578 USD* | 35,535,130 USD | 41,367,009 USD | 18,572,026 USD | 16,023,679 USD | 16,563,176 USD | 16,177,812 USD |
| -3,383,998 USD | -36,029,293 USD | -29,937,807 USD | -38,192,414 USD* | -35,215,717 USD | -40,984,035 USD | -12,618,990 USD | -15,707,145 USD | -16,127,329 USD | -15,695,998 USD | |
| Finance income | 2,560 USD | 472,587 USD | 2,441,677 USD | 2,071,761 USD | 742,828 USD | 113,324 USD | 518,975 USD | 1,701,281 USD | 762,600 USD | 1,237,723 USD |
| Finance costs | 428,747 USD | 670,257 USD | 951,998 USD | 1,010,730 USD | 707,813 USD | 407,592 USD | 287,304 USD | 218,953 USD | 10,078,962 USD | 122,072,273 USD |
| Other income | 33,130 USD | 362,266 USD | 372,210 USD | 230,417 USD* | 175,884 USD | 301,503 USD | 4,845,851 USD | 1,250,674 USD | 677,388 USD | 2,798,091 USD |
| Other expenses | 78,712 USD | 994,482 USD | 1,218,744 USD | 5,322,897 USD* | 302,800 USD | 224,276 USD | 59,934 USD | 26,535 USD | 83,245 USD | 1,666,102 USD |
| -3,855,767 USD | -36,859,179 USD | -29,294,662 USD | -42,223,863 USD* | -35,307,618 USD | -41,201,076 USD | -7,601,402 USD | -13,000,678 USD | -24,849,548 USD | -135,398,559 USD | |
| Income tax expense | -1,595,990 USD | 3,317,012 USD | 29,490 USD | 44,410 USD | 104,811 USD | 190,726 USD | -1,018,291 USD | 193,923 USD | 69,996 USD | 14,722 USD |
| -2,259,777 USD | -40,176,191 USD | -29,324,152 USD | -42,268,273 USD* | -35,412,429 USD | -41,391,802 USD | -8,619,693 USD | -13,194,601 USD | -24,779,552 USD | -135,413,281 USD | |
| Attributable to owners | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Attributable to minorities | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| -2,259,777 USD | -40,082,708 USD | -29,409,782 USD | -42,198,501 USD* | -35,386,697 USD | -41,524,595 USD | -8,658,714 USD | -13,198,567 USD | -24,651,951 USD | -135,557,905 USD | |
| Other comprehensive income | 0 USD | 93,483 USD | -85,630 USD | 69,772 USD* | 25,732 USD | -132,793 USD | -39,021 USD | -3,966 USD | 127,601 USD | -144,624 USD |
| 해외사업장환산외환차이(세후기타포괄손익)As filed | — | — | — | — | — | — | — | 26,297 USD | 194,521 USD | — |
| 확정급여제도의 재측정요소As filed | 0 USD | -16,817 USD | 99,265 USD | -122,810 USD | 43,343 USD | -111,679 USD | 3,822 USD | -30,263 USD | -66,920 USD | -100,609 USD |
| 해외사업환산손익As filed | 0 USD | 110,300 USD | -184,895 USD | 192,583 USD | -17,611 USD | -21,114 USD | -42,843 USD | — | — | -44,015 USD |
Cash flow statement
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net incomefrom the income statement | -2,259,777 USD | -40,176,191 USD | -29,324,152 USD | -42,268,273 USD | -35,412,429 USD | -41,391,802 USD | -8,619,693 USD | -13,194,601 USD | -24,779,552 USD | -135,413,281 USD |
| Total adjustments to operating cash flowcomputed | -754,462 USD | 5,851,416 USD | -1,738,601 USD | 4,644,202 USD | 3,104,272 USD | 6,422,186 USD | -12,105,282 USD | -5,273,975 USD | 9,785,400 USD | 118,528,366 USD |
| -3,014,239 USD | -34,324,775 USD | -31,062,753 USD | -37,624,071 USD* | -32,308,157 USD | -34,969,616 USD | -20,724,975 USD | -18,468,576 USD | -14,994,152 USD | -16,884,915 USD | |
| Interest received | 2,560 USD | 6,021 USD | 1,892,681 USD | 2,510,873 USD* | 1,104,836 USD | 180,704 USD | 285,153 USD | 1,846,650 USD | 823,775 USD | 1,000,196 USD |
| Interest paid | 415,260 USD | 643,774 USD | 949,505 USD | 796,739 USD | 317,028 USD | 104,684 USD | 0 USD | 0 USD | Not applicable | Not applicable |
| Depreciation | 215,181 USD | 356,440 USD | 455,533 USD | 378,315 USD* | 512,127 USD | 524,371 USD | 549,067 USD | 422,719 USD | 332,112 USD | 260,363 USD |
| Amortisation | 112,898 USD | 142,649 USD | 158,542 USD | 138,725 USD | 76,089 USD | 76,633 USD | 76,003 USD | 87,132 USD | 29,292 USD | 20,885 USD |
| Income taxes paid | 1,718,399 USD | 1,682 USD | 0 USD | 0 USD | Not applicable | Not applicable | 1,019,844 USD | 192,860 USD | -70,208 USD | 19,211 USD |
| -216,330 USD | -148,520,000 USD | 24,323,313 USD | 63,714,459 USD* | 15,853,232 USD | 29,201,394 USD | -31,004,790 USD | -22,245,482 USD | -56,632,314 USD | -92,565,639 USD | |
| Purchase of property, plant and equipment | 206,264 USD | 294,092 USD | 432,324 USD | 1,728,346 USD* | 700,597 USD | 478,876 USD | 53,038 USD | 199,615 USD | 94,767 USD | 841,069 USD |
| Proceeds from sale of property, plant and equipment | Not applicable | Not applicable | Not applicable | 101,916 USD* | 0 USD | 222 USD | 0 USD | 1,044 USD | 1,459 USD | 42,300 USD |
| Purchase of intangible assets | 10,066 USD | 1,835 USD | 4,180,145 USD | 299,574 USD* | 10,939 USD | 4,883,663 USD | 18,789,575 USD | 35,189,870 USD | 56,542,851 USD | 81,752,540 USD |
| 16,999,995 USD | 190,085,554 USD | -1,784,725 USD | -5,069,732 USD | -5,833,912 USD | 21,479,773 USD | 51,789,507 USD | 29,188,083 USD | 50,930,593 USD | 156,135,025 USD | |
| Issue of shares | 9,999,995 USD | 181,689,204 USD | 0 USD | 0 USD | — | 29,907,801 USD | 28,644,351 USD | 30,062,507 USD | 34,411,471 USD | 29,998,185 USD |
| Cash at beginning of period | 5,659,101 USD | 19,428,527 USD | 26,735,368 USD | 18,244,010 USD | 39,312,835 USD | 17,023,998 USD | 32,739,992 USD | 32,796,306 USD | 21,275,420 USD | 546,173 USD |
| 19,428,527 USD | 26,735,368 USD | 18,244,010 USD | 39,312,835 USD | 17,023,998 USD | 32,739,992 USD | 32,796,306 USD | 21,275,420 USD | 546,173 USD | 47,210,417 USD | |
| Effect of exchange rate changes | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | -20,227 USD |
| Net change in cash and cash equivalents | 13,769,426 USD | 7,306,841 USD | -8,491,358 USD | 21,068,825 USD | -22,288,837 USD | 15,715,994 USD | 56,314 USD | -11,520,886 USD | -20,729,247 USD | 46,664,244 USD |
| 1.당기순이익(손실)As filed | -2,259,777 USD | -40,176,191 USD | -29,324,152 USD | -42,268,273 USD | -35,412,429 USD | -41,391,802 USD | -8,619,693 USD | — | — | — |
| Ⅳ.외화현금성자산의 환율변동효과As filed | — | — | — | 48,169 USD | 0 USD | 4,443 USD | -3,428 USD | 5,089 USD | -33,374 USD | — |
| 전환사채의 증가As filed | — | — | — | — | — | — | — | — | 17,465,292 USD | 126,571,253 USD |
| 2.현금의 유출이 없는 비용등의 가산As filed | 820,955 USD | 5,048,577 USD | 3,201,067 USD | 7,646,453 USD | 2,378,900 USD | 2,175,726 USD | 2,987,100 USD | 1,588,959 USD | 10,691,665 USD | — |
| 이자비용As filed | 428,747 USD | 670,257 USD | 951,998 USD | 1,010,730 USD | 707,813 USD | 407,592 USD | 287,304 USD | — | — | — |
| 주식선택권행사로 인한 현금유입As filed | — | — | — | — | 0 USD | 0 USD | 277,952 USD | 18,291 USD | — | 561,568 USD |
| 리스부채의 상환As filed | — | — | — | -269,732 USD | -833,912 USD | -928,028 USD | -853,879 USD | -892,715 USD | -931,569 USD | — |
| 사용권자산감가상각비As filed | — | — | — | 589,061 USD | 803,635 USD | 754,145 USD | 663,669 USD | 571,584 USD | 231,386 USD | — |
| 전환사채의 전환As filed | — | — | — | — | — | — | — | — | — | 11,886 USD |
| 주식보상비용(환입)As filed | 64,129 USD | 173,043 USD | — | — | — | — | — | — | — | — |
| 영구전환사채의 전환As filed | — | — | — | — | — | — | — | — | -14,601 USD | — |
| 주식보상비용As filed | — | — | 44,031 USD | 21,023 USD | 1,123 USD | 0 USD | 0 USD | 59,075 USD | 58,049 USD | — |
| 리스부채의 지급As filed | — | — | — | — | — | — | — | — | — | 984,095 USD |
| 신종자본증권의 발행As filed | — | — | — | — | — | — | 23,721,083 USD | 0 USD | — | — |
| 퇴직급여As filed | 0 USD | 72,731 USD | 251,639 USD | 129,978 USD | 131,239 USD | 93,624 USD | 98,138 USD | — | — | — |
| 단기금융상품의 감소As filed | — | — | — | 65,640,463 USD | 51,423,755 USD | 35,742,633 USD | 1,122,355 USD | 33,556,036 USD | — | 7,000,000 USD |
| 유형자산폐기손실As filed | 0 USD | 3,070 USD | 30,381 USD | 0 USD | 0 USD | 12,169 USD | 0 USD | — | — | — |
| 차입금의 상환As filed | — | — | — | — | — | 7,500,000 USD | 0 USD | 0 USD | — | — |
| 대손상각비As filed | — | — | 75,648 USD | 106,468 USD | -76,119 USD | -94,078 USD | 187,234 USD | — | — | — |
| 기타의 대손상각비As filed | — | — | 8,079 USD | 1,076 USD | 468 USD | 172,699 USD | 3,584 USD | — | — | — |
| 단기금융상품의 취득As filed | 0 USD | 146,000,000 USD | 0 USD | 0 USD | 34,750,000 USD | 1,161,360 USD | 13,163,493 USD | 20,383,021 USD | — | 17,000,000 USD |
| 대여금의 감소As filed | — | — | — | — | 13,484 USD | 60,500 USD | 0 USD | 0 USD | — | — |
| 무형자산손상차손As filed | 0 USD | 71,557 USD | 781,647 USD | 5,162,708 USD | 0 USD | 0 USD | — | — | — | — |
| 보증금의 감소As filed | — | — | — | — | — | — | — | — | 29,845 USD | — |
| 유형자산처분손실As filed | — | — | 31,078 USD | 28,939 USD | 0 USD | 1,019 USD | 0 USD | — | — | — |
| 임차보증금의 증가As filed | — | — | — | — | — | — | — | 30,605 USD | — | — |
| 재고자산평가손실As filed | 0 USD | 240,378 USD | 86,480 USD | 35,014 USD | -166,505 USD | -3,962 USD | -22,600 USD | — | — | — |
| 법인세비용As filed | 0 USD | 3,317,012 USD | 29,490 USD | 44,410 USD | 104,811 USD | 190,726 USD | 1,018,291 USD | — | — | — |
| 보증금의 증가As filed | — | — | — | — | — | — | — | — | -26,000 USD | — |
| 투자활동으로 분류된 보증금의 감소As filed | — | — | — | — | — | — | — | — | — | 0 USD |
| 투자활동으로 분류된 보증금의 증가As filed | — | — | — | — | — | — | — | — | — | 14,330 USD |
| 4.순운전자본 변동As filed | 2,187,362 USD | 1,925,340 USD | -3,564,473 USD | -2,644,549 USD | 680,816 USD | 4,340,728 USD | -9,205,893 USD | -5,877,007 USD | -473,800 USD | — |
| 유형자산손상차손As filed | — | — | — | — | 0 USD | 0 USD | — | — | — | — |
| 잡손실As filed | 0 USD | 1,440 USD | 0 USD | — | — | — | — | — | — | — |
| 보증금의 회수As filed | — | — | — | — | — | 62,632 USD | -121,039 USD | 549 USD | — | — |
| 3.현금의 유입이 없는 수익등의 차감As filed | -1,631,680 USD | -483,066 USD | -2,318,371 USD | -2,071,836 USD | — | — | — | — | — | — |
| 기타채권(유동)As filed | — | — | — | -1,833,384 USD | 1,875,761 USD | -111,241 USD | -324,668 USD | 309,298 USD | -3,044 USD | — |
| 리스자산해지손실As filed | — | — | — | — | 288 USD | 0 USD | 0 USD | — | — | — |
| 무형자산폐기손실As filed | — | — | 909 USD | 0 USD | 0 USD | — | — | — | — | — |
| 순운전자본 변동As filed | — | — | — | — | — | — | — | — | — | -3,221,101 USD |
| 법인세수익As filed | -1,595,990 USD | 0 USD | 0 USD | — | — | — | — | — | — | — |
| 확정급여채무의현재가치의 증가(감소)As filed | — | — | — | — | — | — | — | — | -107,523 USD | — |
| 기타채권의 감소(증가)As filed | — | — | — | — | — | — | — | — | — | -51,262 USD |
| 기타유동부채의 증가(감소)As filed | — | — | — | — | — | — | — | — | — | 2,552,735 USD |
| 당기법인세자산As filed | — | — | -588 USD | — | — | -190,960 USD | 0 USD | 0 USD | — | — |
| 이자수익As filed | -2,560 USD | -472,587 USD | -2,318,053 USD | -2,071,761 USD | -742,828 USD | -113,324 USD | -518,975 USD | -1,701,281 USD | -762,600 USD | — |
| 충당부채의 증가(감소)As filed | — | — | — | -58,174 USD | -38 USD | -64,694 USD | 2,763 USD | 11,115 USD | -16,893 USD | 16,832 USD |
| 외화환산이익As filed | -33,130 USD | 0 USD | 0 USD | — | 0 USD | -56,228 USD | -1,014,416 USD | -14,336 USD | -563,100 USD | — |
| 재고자산폐기손실As filed | — | — | 48,357 USD | 0 USD | 241,904 USD | 40,788 USD | 72,626 USD | 0 USD | — | — |
| 기타비유동자산As filed | 0 USD | -279,325 USD | 228,426 USD | 314,868 USD | 1,198,414 USD | -2,300,393 USD | -3,181,741 USD | -437,984 USD | — | — |
| 기타채무(유동)As filed | 1,939,150 USD | 3,222,499 USD | -2,353,467 USD | 99,717 USD | 1,121,997 USD | 5,357,751 USD | -6,724,969 USD | -1,921,852 USD | 4,873,597 USD | — |
| 대손충당금환입As filed | 0 USD | -10,479 USD | 0 USD | 0 USD | — | 0 USD | — | — | — | — |
| 기타비유동부채의 증가(감소)As filed | — | — | — | — | — | 0 USD | -6,192 USD | -17,619 USD | — | — |
| 외화환산손실As filed | — | — | — | 6 USD | 42,027 USD | 0 USD | 53,784 USD | — | — | — |
| 재고자산의 감소(증가)As filed | — | — | — | — | — | — | — | — | — | 24,226 USD |
| 전환사채As filed | — | — | — | — | — | — | — | — | -13,288 USD | — |
| 지급보증수수료As filed | — | — | 247,255 USD | 0 USD | 0 USD | — | — | — | — | — |
| 3. 현금의 유출이 없는 수익등의 차감As filed | — | — | — | — | -743,252 USD | -170,288 USD | -5,151,798 USD | -2,639,717 USD | -1,326,448 USD | — |
| 기타채무(비유동)As filed | 0 USD | -52,502 USD | -237,943 USD | -325,552 USD | 0 USD | 0 USD | -151,743 USD | 0 USD | — | — |
| 기타유동자산의 감소(증가) 조정As filed | — | — | — | — | — | — | — | — | — | -923,149 USD |
| 매출채권As filed | 0 USD | 368,678 USD | 75,017 USD | -514,328 USD | 285,432 USD | 300,211 USD | 45,435 USD | — | — | — |
| 재고자산As filed | 0 USD | 39,863 USD | -48,357 USD | 199,660 USD | 52,319 USD | 108,709 USD | 69,186 USD | -36,330 USD | -25,336 USD | — |
| 기타유동자산As filed | -455,440 USD | -1,163,621 USD | -911,315 USD | -457,651 USD | -3,706,839 USD | 1,795,760 USD | 26,205 USD | -3,970,431 USD | -5,384,974 USD | — |
| 매출채권의 감소(증가)As filed | — | — | — | — | — | — | — | -92,217 USD | -42,000 USD | 19,942 USD |
| 유형자산처분이익As filed | — | — | -318 USD | -75 USD | -424 USD | -199 USD | 0 USD | 0 USD | — | — |
| 확정급여채무As filed | 0 USD | -306,485 USD | -359,969 USD | -35,617 USD | 0 USD | -183,954 USD | -122,863 USD | -71,437 USD | — | — |
| 기타채권As filed | 83,466 USD | -64,051 USD | 117,166 USD | — | — | — | — | — | — | — |
| 기타유동부채As filed | 259,097 USD | -401,237 USD | -38,721 USD | -69,915 USD | 348,296 USD | -237,987 USD | 1,153,142 USD | 234,919 USD | 192,969 USD | — |
| 리스자산해지이익As filed | — | — | — | — | — | -537 USD | 0 USD | 0 USD | — | — |
| 순확정급여부채의 증가(감소)As filed | — | — | — | — | — | — | — | — | — | -115,124 USD |
| 매입채무As filed | 0 USD | 37,336 USD | -120,689 USD | 35,576 USD | -185,464 USD | -132,474 USD | 9,552 USD | 115,531 USD | 52,692 USD | — |
| 기타유동채무의 증가(감소)As filed | — | — | — | — | — | — | — | — | — | -4,731,630 USD |
| 기타영업외수익As filed | — | — | — | — | — | — | -3,618,407 USD | -924,100 USD | — | — |
| 매입채무의 증가(감소)As filed | — | — | — | — | — | — | — | — | — | -13,671 USD |
| 당기순이익조정을 위한 가감As filed | — | — | — | — | — | — | — | — | — | 120,768,482 USD |
| 기타금융자산As filed | 0 USD | -34,983 USD | -25,000 USD | — | — | — | — | — | — | — |
| 대손상각비 조정As filed | — | — | — | — | — | — | — | -22,651 USD | 2,301 USD | 20,942 USD |
| 유형자산처분이익(손실)에 대한 조정As filed | — | — | — | — | — | — | — | — | -748 USD | — |
| 사용권자산감가상각비 조정As filed | — | — | — | — | — | — | — | — | — | 270,017 USD |
| 유형자산처분이익 조정As filed | — | — | — | — | — | — | — | — | — | 43,214 USD |
| 이자비용 조정As filed | — | — | — | — | — | — | — | 218,953 USD | 65,873 USD | 63,002 USD |
| 기타의 대손상각비 조정As filed | — | — | — | — | — | — | — | 5,274 USD | 244 USD | — |
| 외화환산이익 조정As filed | — | — | — | — | — | — | — | — | — | 805,917 USD |
| 기타비유동부채As filed | -1,257 USD | 0 USD | 154 USD | 0 USD | 0 USD | — | — | — | — | — |
| 퇴직급여 조정As filed | — | — | — | — | — | — | — | 51,511 USD | 25,369 USD | 87,543 USD |
| 유형자산처분손실 조정As filed | — | — | — | — | — | — | — | 0 USD | — | 16,951 USD |
| 재고자산평가손실 조정As filed | — | — | — | — | — | — | — | -225 USD | 3,946 USD | — |
| 정부보조금수령As filed | 362,346 USD | 559,168 USD | 110,813 USD | — | — | — | — | — | — | — |
| 파생금융부채평가손실As filed | — | — | — | — | — | — | — | — | 10,013,089 USD | 119,979,473 USD |
| 외화환산손실 조정As filed | — | — | — | — | — | — | — | 0 USD | — | 13,440 USD |
| 기타금융자산의 감소(증가)As filed | — | — | — | 0 USD | 0 USD | — | — | — | — | — |
| 사업결합As filed | 0 USD | -2,224,073 USD | 0 USD | 0 USD | — | — | — | — | — | — |
| 기타의 대손충당금환입As filed | — | — | — | — | — | — | — | — | — | 21 USD |
| 당기법인세자산의 감소(증가)As filed | — | — | — | 251 USD | -114,029 USD | — | — | — | — | — |
| 법인세비용 조정As filed | — | — | — | — | — | — | — | 193,923 USD | -69,996 USD | 14,722 USD |
| 단기차입금의 증가As filed | 0 USD | 5,000,000 USD | 0 USD | 0 USD | — | — | — | — | — | — |
| 당기순이익(손실)As filed | — | — | — | — | — | — | — | — | -24,779,552 USD | -135,413,281 USD |
| 재고자산평가손실환입 조정As filed | — | — | — | — | — | — | — | — | — | 1,041 USD |
| 장기차입금의 증가As filed | 7,000,000 USD | 6,000,000 USD | 0 USD | 0 USD | — | — | — | — | — | — |
| 주식보상비용(환입) 조정As filed | — | — | — | — | — | — | — | — | — | 79,262 USD |
| 거래일이연손익 조정As filed | — | — | — | — | — | — | — | — | — | 2,029,798 USD |
| 유형자산폐기손실 조정As filed | — | — | — | — | — | — | — | 1,664 USD | — | — |
| 주식선택권행사As filed | 0 USD | 396,350 USD | 2,715,275 USD | 200,000 USD | — | — | — | — | — | — |
| 단기차입금의 상환As filed | 0 USD | 3,000,000 USD | 4,500,000 USD | 5,000,000 USD | 5,000,000 USD | — | — | — | — | — |
| 정부보조금의 수령As filed | — | — | — | 0 USD | 0 USD | — | — | — | — | — |
| IV.현금및현금성자산의 환율변동효과As filed | 0 USD | 66,062 USD | 32,807 USD | — | — | — | — | — | — | — |
| 이자수익에 대한 조정As filed | — | — | — | — | — | — | — | — | — | 1,237,723 USD |
| 퇴직금의 지급As filed | — | — | — | — | -3,536 USD | 0 USD | — | — | — | — |
| 관계사전출입As filed | — | — | — | — | — | 0 USD | — | — | — | — |
| 관계사 전출입As filed | — | — | — | — | -191,497 USD | — | — | — | — | — |
| 기여금의 납입As filed | — | — | — | — | 0 USD | 0 USD | — | — | — | — |
| 단기금융상품의 처분As filed | — | — | 28,935,782 USD | — | — | — | — | — | — | — |
| 보증금의 상환As filed | — | — | — | — | — | -140,694 USD | 0 USD | — | — | — |
| 대여금의 증가As filed | — | — | — | — | 14,001 USD | 0 USD | 0 USD | — | — | — |
| 당기순이익As filed | — | — | — | — | — | — | — | -13,194,601 USD | — | — |
| 임차보증금의 감소As filed | — | — | — | — | -108,470 USD | — | — | — | — | — |
In the latest fiscal year operations and investing consumed cash raised through financing activities.
Periods filed in a currency other than the won are shown as filed with the code beside the figure, and the per-share rows and multiples are not computed for those periods.
A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.
Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.
The newest annual filing shown was received on 2026.03.18.
Audit opinion
| Fiscal year | Opinion | Auditor | Fiscal year end |
|---|---|---|---|
| 2025 | 적정의견Term 27 | 서현회계법인 | 2025-12-31 |
| 2024 | 적정의견Term 26 | 서현회계법인 | 2025-12-31 |
| 2023 | 적정의견Term 25 | 서현회계법인 | 2025-12-31 |
| 2022 | 적정Term 24 | 서현회계법인 | 2022-12-31 |
| 2021 | 적정Term 23 | 서현회계법인 | 2022-12-31 |
| 2020 | 적정Term 22 | 서현회계법인 | 2022-12-31 |
| 2019 | 의견거절(*3)Term 21 | 한영회계법인 | 2019-12-31 |
| 2018 | 의견거절(*2)Term 20 | 한영회계법인 | 2019-12-31 |
| 2017 | 의견거절(*1)Term 19 | 한영회계법인 | 2019-12-31 |
The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.
Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.